Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-...19 policy advice to WHO member states and in particular the advice on how to reach the COVID-19 vaccination targets.
more
Ethnic disparities in COVID-19 persist, with increased rates of infection, severe disease, and death among people from minority ethnic groups. COVID-19 vaccination rates also remain lowest in these communities compared with white people in the UK. Among people older than 18 years, the proportion who... have had three COVID-19 vaccinations in England in March, 2022, was lowest among Black Caribbean (38%), Black African (45%), and Pakistani (45%) ethnic groups. These disparities are likely to be attributed to the intersection of key social determinants, including socioeconomic factors such as deprivation, overcrowding, and working patterns and conditions,
alongside discrimination and structural violence in the health-care system and society.
more
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
Additional dose of the primary vaccination against COVID-19: Technical Guidelines
Guidelines for the Vaccination Scheme against
COVID 19: Booster Dose Health Personnel